Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the PresidentÃ¢ÂÂs Cancer Panel Report on HPV Vaccinations
Eva McGhee*, Hill Harper, Adaku Ume, Melanie Baker, Cheick Diarra, John Uyanne, Sebhat Afework, Keosha Partlow, Lucy Tran, Judith Okoro, Anh Doan, Karen Tate, Mechelle Rouse, Meidrah Tyler, Kamilah Evans, Tonya Sanchez, Ishmum Hasan, Enijah Smith-Joe, Jasmine Maniti, Liliana Zarate, Camille King, Antoinette Alugbue, Chiamaka Opara, Bileko Wissa, Joanne Maniti and Roland Pattillo
Department of Internal Medicine, Charles Drew University of Medicine and Science, Los Angeles, USA
- *Corresponding Author:
- Eva McGhee
Department of Internal Medicine, Charles Drew University of Medicine and Science
1731 East 120th Street, Los Angeles, CA-90059, USA
E-mail: [email protected]
Received date: May 02, 2017; Accepted date: May 25, 2017; Published date: May 29, 2017
Citation: McGhee E, Harper H, Ume A, Baker M, Diarra C, et al. (2017) Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President’s Cancer Panel Report on HPV Vaccinations. J Vaccines Vaccin 8:361. doi:10.4172/2157-7560.1000361
Copyright: © 2017 McGhee E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The human papillomavirus (HPV) is a major public health concern affecting both females and males. HPV is associated with cervical, anal, head and neck cancers. About 99% of all cervical cancers are related to HPV. HPV vaccines, Gardasil, Cervarix, and Gardasil 9 are used in the primary prevention of HPV related cancers. Gardasil and Gardasil 9 are available for use in both females and males ages 9 to 26, while Cervarix is available for females ages 9 to 25. Gardasil 9 was approved by the FDA for prevention against additional HPV types. Despite the availability of this preventative measure against cervical cancer, the rate of HPV vaccination in the United States remains lower than that of other industrialized nations. The purpose of this study is to elucidate mechanisms to help increase the HPV vaccination rate by using education as a tool; by simplifying the president report so that lay person can understand the information presented in the report. Through the quantitative examination of the data from the states with the lowest and highest vaccination rates, using SPSS statistical analysis; we analyzed several factors involved with the low uptake of the vaccines. The results collected show that socioeconomic status, misconceptions about HPV, and misconceptions about the safety of the vaccines were identified as possible obstacles to the effective uptake of HPV vaccinations. The proposals made by the President's Cancer Panel to accelerate the uptake of vaccines include, increasing coverage of the vaccines through government-sponsored programs, and the Affordable Care Act; increasing accessibility to vaccines through pharmacies, schools, and clinics; and disseminating more information on HPV to healthcare providers, parents, caregivers, and patients. Allowing greater accessibility to the vaccines for all populations regardless of income, education, and eliminating misconceptions of the vaccines would play a significant role in eliminating cancer.